Opinions
Jonathen Wellum, B. Comm, B. Sc
Quest Diagnostics Inc.
DGX-N
BUY
Jul 26, 2007
A leading laboratory and diagnostic business. Less susceptible to changes that could occur in the health sector in the US. Very profitable with a lot of free cash flow. Very defensive.
$55.870
Stock price when the opinion was issued
medical services
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Benefits from the coronavirus. They run a national lab diagnostics and testing business. They have an immediate tailwind from the US about to mass-test people for the virus. Good price momentum, low-vol and trades at a 14% ROE at a so-so 20x earnings. (Analysts’ price target is $112.79)
medical services
PAST TOP PICK
(A Top Pick Mar 10/20, Up 22%) National diagnostic and testing in US and Canada. Picked this for covid mass testing capabilities. Stock has done reasonably well. Still cheap and cheaper than in March due to growing into valuation. 7.8x EBITDA, 23% ROE and 12x earnings. Great balance sheet. Low pay out ratio, smaller yield.
medical services
Advertising